December 28, 2023 – The National Medical Products Administration (NMPA) approved TNP-2092 ointment to conduct a Phase I/II clinical trial for the treatment of diabetic foot infection (DFI).

DFI is an important cause of disease progression, amputation, and death in patients with diabetes. Due to various factors such as decreased immunity of patients with diabetes, antibiotic resistance, bacterial biofilm formation, and limited delivery of systemic antibiotics to the site of infection, the treatment of DFI is extremely difficult. There are unmet needs for the treatment of DFI. TNP-2092 is a multi-targeting drug conjugate developed by TenNor Therapeutics. It exerts its bactericidal activity through the synergistic mechanism of action of inhibiting bacterial RNA polymerase, DNA gyrase and topoisomerase IV. TNP-2092 has strong bactericidal activity against the common pathogens causing DFI, including methicillin-resistant Staphylococcus aureus (MRSA) and bacteria living in bacterial biofilms. Through local administration, TNP-2092 ointment can significantly increase the drug concentration at the infected site and reduce the safety risks caused by systemic exposure. TNP-2092 is expected to further improve the safety and effectiveness of DFI treatment.

TenNor has completed more than 10 clinical studies for TNP-2092 injections and oral dosage forms and the safety and efficacy of TNP-2092 have been demonstrated in multiple indications. TNP-2092 has received Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of prosthetic joint infections.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com